In summary, our study uncovers a novel mechanism involving FTO-mediated m6A demethylation orchestrating IGF1R mRNA modification through YTHDF2, thereby offering promising avenues for targeted FTO modulation in the treatment of hypertensive disorders in PE, ultimately translating to improved outcomes for both mothers and fetuses. This evidence concerns the gene FTO and hypertensive disorder.